Corbus Pharmaceuticals Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRBP research report →
Range $33 – $35
Price Chart
About the company
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
- CEO
- Yuval Cohen
- IPO
- 2014
- Employees
- 36
- HQ
- Norwood, MA, US
Get TickerSpark's AI analysis on CRBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.45M
- P/E
- -0.43
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 0.67
- EV/EBITDA
- -0.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -100.96%
- ROIC
- -136.79%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-85,310,000
- Net Income
- $-78,537,000-95.3%
- EPS
- $-5.90-60.3%
- OCF Growth
- -54.3%
- FCF Growth
- -54.3%
- 52W High
- $12.88
- 52W Low
- $2.01
- 50D MA
- $5.12
- 200D MA
- $8.26
- Beta
- 2.79
- RSI (14)
- 25
- Avg Volume
- 1.10M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Corbus said its Phase 3 dermatomyositis readout remains on track for the second quarter, while the company highlighted a strengthened cash position and confidence in its internal CB1/CB2 pipeline.· March 15, 2021
- All patients in the Phase 3 DETERMINE dermatomyositis study completed the week 28 visit; topline data is still expected in the second quarter.
- Management moved the primary endpoint from week 52 to week 28 and said the study’s outcome will determine next steps for lenabasum and the systemic sclerosis program.
- Corbus said it had approximately $127 million of cash as of March 15, 2021, which it expects to fund operations into the first quarter of 2024.
- The company said its CB1 inverse agonist and CB2 agonist programs are advancing, with lead compounds anticipated to enter clinical studies in 2022.
- Management is not currently considering additional lenabasum studies in cystic fibrosis, but is analyzing post-hoc data for pulmonary exacerbations.
Corbus did not report quarterly revenue or EPS on this call. It said cash on hand was approximately $127 million as of March 15, 2021, and expects that capital to fund operations into the first quarter of 2024 based on its current budget. Management said all patients in the Phase 3 DETERMINE dermatomyositis study completed the week 28 visit, the primary efficacy endpoint after a protocol amendment from week 52 to week 28, and topline data remains expected in the second quarter. The CFO said the company projects about a $10 million average cash burn going forward, helped by completed expensive CF and systemic sclerosis studies and a reduction in workforce. No full-year revenue or earnings guidance was provided.
Yuval Cohen framed the quarter as continued execution on a three-part strategy: maximize lenabasum value, advance internal programs toward clinical testing in 2022, and pursue external pipeline opportunities. He said the company believes lenabasum remains an active compound and called the dermatomyositis readout a potentially significant inflection point. His tone was constructive and focused on optionality, emphasizing that Corbus has the resources to move multiple programs forward without a financing overhang.
Sean Moran focused on the balance sheet and burn reduction. He said the prior burn reflected the costs of two pivotal studies in cystic fibrosis and systemic sclerosis, while the reduction in workforce lowered personnel expenses; as a result, Corbus now projects about a $10 million average burn going forward. He said the $127 million cash position should support development of the company’s compounds into Phase 1 studies and fund operations into the first quarter of 2024.
Analysts asked how close the company is to selecting candidates for its CB1 inverse agonist and CB2 agonist programs, and Barbara White said she is quite confident the team will get there, citing promising compounds and ongoing work to minimize brain CB1 receptor occupancy, with candidate selection targeted by the end of the year or perhaps before year-end. On cash, management explained the lower burn by pointing to the completion of expensive CF and systemic sclerosis studies and workforce reductions, and said the $10 million average burn already contemplates moving compounds into Phase 1. Analysts also pressed on the implications of Roche’s Actemra approval for systemic sclerosis-related interstitial lung disease; management said the approval underscores the need for more treatments, noted its own subgroup data showing less decline in forced vital capacity, and said it will first wait for dermatomyositis data before deciding whether to pursue an FDA path, likely in the second half of the year.
The bull case from this call is that Corbus is close to a major binary catalyst in dermatomyositis, with all patients through the key week 28 endpoint and topline expected soon. Management also sounded confident that its internal CB1 and CB2 programs are maturing, and the $127 million cash balance gives it runway into 2024 to pursue the pipeline without immediate financing pressure.
The main risk is that the upcoming dermatomyositis readout will determine the future of lenabasum, so a weak result could significantly affect the company’s direction. Management also acknowledged uncertainty around whether the FDA’s Actemra decision reflects a one-off or a broader openness to subset analyses, and said any systemic sclerosis path depends on additional data after the DM readout. The company is also no longer pursuing additional cystic fibrosis studies, which limits near-term optionality in that program.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.4%
- Shares Outstanding
- 20.61M
- Float Shares
- 13.69M
of shares held by institutions
64 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Exane Derivatives | 2.65K | ▼ 2.12K |
| American Portfolios Advisors | 2.31K | ▲ 100 |
Held by 104 ETFs
Biggest fund positions in CRBP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 26 | Cormorant Asset Management, LP | sell | 425,000 |
| Sep 14, 26 | Ben Yong | sell | 2,000 |
| Aug 16, 26 | Nicacio Leonardo Viana | other | 191,676 |
| Aug 16, 26 | Nicacio Leonardo Viana | other | 58,333 |
| Aug 11, 26 | Saxena Nishant C | buy | 2,600 |
| Aug 7, 26 | Cohen Yuval | sell | 17,000 |
| Aug 7, 26 | Moran Sean F. | sell | 12,000 |
| Aug 3, 26 | Nicacio Leonardo Viana | other | 0 |
| Jun 10, 26 | Kung Winston | sell | 2,026 |
| Jun 10, 26 | Altmeyer Anne | sell | 2,412 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRBP coverage
Recent articles, reports, and earnings notes.
No research on CRBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRBP report →Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Has Average Target Price of $35.67 According to Analysts
defenseworld.net · Nov 19
Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug
marketbeat.com · Nov 18
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
globenewswire.com · Nov 16
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
globenewswire.com · Nov 10
Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data
marketbeat.com · Nov 9
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
globenewswire.com · Nov 5
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Oct 25
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.